Syros Pharmaceuticals Stock News

Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.

Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

A company's size does not necessarily dictate the size of it's returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that will

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.

Syros Pharmaceuticals, Inc. (SYRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that

Syros Pharmaceuticals, Inc. (SYRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The average of price targets set by Wall Street analysts indicates a potential upside of 199.3% in Syros Pharmaceuticals, Inc. (SYRS). While the effectiveness of this highly sought-after metric is que

Syros Pharmaceuticals (SYRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

As the year wound to a close, biotechs were in focus among the notable insider purchases.

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clar

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations & Corporate Communications N

Syros Pharmaceuticals shares dropped on Monday after a series of shakeups at the biotech company. The firm is saying goodbye to its CEO, Nancy Simonian, who will retire by the end of the year, and chi